Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

PURPOSE Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study. Here, we report long-term outcomes from CROWN after 5 years of follow-up. METHODS Two hundred ninety-six patients with ALK -positive NSCLC were randomly assigned 1:1 to receive lorlatinib 100 mg once daily (n = 149) or crizotinib 250 mg twice daily (n = 147). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS With a median follow-up for PFS of 60.2 and 55.1 months, respectively, median PFS was not reached (NR [95%…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• GS
  Gilead Sciences
• RP
  Regeneron Pharmaceuticals
• TP
  Taiho Pharmaceutical
• JP
  Jazz Pharmaceuticals
• B
  BeiGene
• L
  Lunit
• SE
  Sociedad Española de Oncología Médica
• G
  Grifols
• G
  Genentech
• DS
  Daiichi Sankyo Europe